Misago M, Chiba S, Tsukada J, Nakata K, Sato T, Nagata K, Mori N, Wake A, Ogawa R, Kikuchi M
First Department of Internal Medicine, School of Medicine, University of Occupational and Environmental Health, Kitakyu-shu, Japan.
Gan To Kagaku Ryoho. 1991 May;18(6):1007-11.
From July 1983 to December 1989, 31 previously untreated patients with non-Hodgkin's lymphoma were treated with modified CHOP regimen (cyclophosphamide 300 mg/m2 on day 1, aclacinomycin 40 mg/m2 on day 1, vincristine 0.7 mg/m2 on day 1 and prednisolone 40 mg/m2 on days 1-5). The therapy was repeated at 2-week intervals. The complete response rate was 66.7% for clinical stage (CS) II according to the Ann Arbor criteria, 60.0% for CS III and 33.3% for CS IV, respectively. The 5-year survival rate was 100% for CS II, 36.6% for CS III and 34.6% for CS IV, respectively. Clinical effects of modified CHOP regimen were almost the same as those of other therapies including adriamycin from the standpoint of 5-year survival rate. On the other hand, the myelosuppression accompanying modified CHOP therapy was not severe. Only one patient had a white blood count below 1,000/microliters during 6 courses of the therapy. It is thought that this regimen is useful to enhance the quality of life of patients because of no severe complications such as myelosuppression.
1983年7月至1989年12月，31例未经治疗的非霍奇金淋巴瘤患者接受改良CHOP方案治疗（环磷酰胺300mg/m²，第1天；阿克拉霉素40mg/m²，第1天；长春新碱0.7mg/m²，第1天；泼尼松龙40mg/m²，第1 - 5天）。治疗每2周重复一次。根据Ann Arbor标准，临床分期（CS）II期的完全缓解率为66.7%，CS III期为60.0%，CS IV期为33.3%。5年生存率分别为CS II期100%，CS III期36.6%，CS IV期34.6%。从5年生存率来看，改良CHOP方案的临床效果与包括阿霉素在内的其他疗法几乎相同。另一方面，改良CHOP治疗伴随的骨髓抑制并不严重。在6个疗程的治疗中，只有1例患者白细胞计数低于1000/微升。由于没有骨髓抑制等严重并发症，认为该方案有助于提高患者的生活质量。
